Inducible T-cell co-stimulator, also known as ICOS, is a human gene. CD278 or ICOS (I nducible T-cell COS timulator) is a CD28-superfamily costimulatory molecule that is expressed on activated T cells. It is thought to be important for T h 2 cells in particular. The protein encoded by this gene belongs to the CD28 and CTLA-4 cell-surface receptor family.
Discovers and develops treatment for inflammation and other diseases, targeting the earliest stages of the inflammation process. Includes expression and production in Bothell ...
ICOS Corporation was a biotechnology company based in Bothell, Washington that began operations in 1990 after being co-founded by Dr. George B. Rathmann, previously CEO and co-founder of Amgen Inc. and a pioneer in the biotechnology industry. During its 17-year history, ICOS conducted clinical trials of many compounds in the areas of sepsis, multiple sclerosis, ischemic stroke, pancreatitis, pulmonary arterial hypertension, COPD, pneumonia sepsis, interstitial cystitis, psoriasis, haemorrhagic shock, and sexual dysfunction.
Develops and supplies machine vision and inspection solutions for use in back-end semiconductor manufacturing and electronic assembly industries. (Nasdaq: IVIS).
Updated 7/31/08. Home. ICOS Abbreviated Who we are and what we're about. Past ICOS Seminars Access to ICOS Syllabi and RealMedia Presentations. Registered Students' Page
Get detailed information on (ICOS) including quote performance, Real-Time ECN, technical chart analysis, key stats, insider transactions, and the latest company headlines.
Sites so far
Leave a reply